Also known as: Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company developing RNA interference medicines for intractable diseases. Its platform seeks to silence disease-causing genes across multiple therapeutic areas.
Arrowhead Pharmaceuticals is in focus after first-quarter results moved from a year-ago loss to profitability and the company shifted from the S&P 600 to the S&P 400. Investors are also watching progress in its RNAi pipeline, including two Phase 3 therapies, while valuation measures show a mixed picture.
Arrowhead Pharmaceuticals presented long-term data showing plozasiran achieved 83% median triglyceride reduction in severe hypertriglyceridemia patients with no acute pancreatitis events over two years. The RNA interference therapy demonstrated durable improvements in atherogenic lipoproteins and consistent safety profile. The company plans to complete Phase 3 studies by mid-2026 and submit for regulatory approval.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07241546 |
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma |
RECRUITING | PHASE2 |
| NCT07221344 |
Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease |
RECRUITING | PHASE1/PHASE2 |
| NCT07037771 |
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) |
RECRUITING | PHASE3 |
| NCT06937203 |
A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus |
RECRUITING | PHASE1/PHASE2 |
| NCT06880770 |
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis |
RECRUITING | PHASE3 |
| NCT06822790 |
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia |
RECRUITING | PHASE3 |
| NCT06700538 |
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus |
RECRUITING | PHASE1/PHASE2 |
| NCT06209177 |
Study of ARO-CFB in Adult Healthy Volunteers |
COMPLETED | PHASE1 |
| NCT05413135 |
Study of ARO-APOC3 in Adults With Dyslipidemia |
COMPLETED | PHASE2 |
| NCT05217667 |
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH) |
TERMINATED | PHASE2 |
